Dapagliflozin

Catalog No.S1548

Dapagliflozin is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 3.

Price Stock Quantity  
In DMSO USD 280 In stock
USD 170 In stock
USD 320 In stock
USD 970 In stock
USD 2470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Dapagliflozin Chemical Structure

Dapagliflozin Chemical Structure
Molecular Weight: 408.87

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

Dapagliflozin is available in the following compound libraries:

Product Information

  • Compare SGLT Inhibitors
    Compare SGLT Inhibitors
  • Research Area

Product Description

Biological Activity

Description Dapagliflozin is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 3.
Targets hSGLT2
IC50 1.1 nM (EC50) [1]
In vitro Dapagliflozin is not sensitive to hSGLT1 with a 1200-fold IC50. [1] Dapagliflozin is 32-fold more potent than phlorizin against hSGLT2 but 4-fold less than phlorizin against hSGLT1. Dapagliflozin is highly selective versus GLUT transporters and displays 8–9% inhibition in protein-free buffer at 20 μM and virtually no inhibition in the presence of 4% bovine serum albumin. [2] Dapagliflozin has good permeability across Caco-2 cell membranes and is a substrate for P-glycoprotein (P-gp) but not a significant P-gp inhibitor. Dapagliflozin is stable in rat, dog, monkey, and human serum at 10 μM. Dapagliflozin shows no inhibitory responses or induction to human P450 enzymes. The in vitro metabolic pathways Dapagliflozin are glucuronidation, hydroxylation, and O-deethylation. [3]
In vivo Dapagliflozin reduces blood glucose levels by 55% after 0.1 mg/kg oral dose in hyperglycemic streptozotocin (STZ) rats, which is in part to the metabolic stability conferred by the C-glucoside linkage. Dapagliflozin displays a favorable absorption, distribution, metabolism, and excretion (ADME) profile and is orally bioavailable. [1] Dapagliflozin (1 mg/kg) causes significant dose-dependent glucosuria and increase in urine volume in normal rats over 24 hours post-dose. Dapagliflozin induces increase in urine glucose and urine volume excretion at 6 hours post-dose in Zucker diabetic fatty (ZDF) rats. Dapagliflozin lowers fasting and fed glucose levels in ZDF rats even by 2 weeks of treatment, without any marker of renal or liver toxicity. [2] Dapagliflozin significantly reduces the development of hyperglycaemia, with lowered blood glucose. Dapagliflozin could improve the insulin sensitivity, reduce β-cell mass and the development of impaired pancreatic function. [4]
Features More potent stimulator of glucosuria than other SGLT2 inhibitors.

Protocol(Only for Reference)

Kinase Assay: [1]

SGLT Binding Assays Chinese hamster ovary (CHO) cells stably expressing human SGLT2 (hSGLT2) and human SGLT1 (\hSGLT1) are utilized for the development of transport assays using the selective SGLT substrate α-methyl-D-glucopyranoside (AMG). Dapagliflozin is assayed for the ability to inhibit [14C]AMG uptake in a protein- free buffer over a 2 hours incubation period. The response curve is fitted to an empirical four-parameter model to determine the inhibitor concentration at half maximal response, reported as EC50. Protein-free buffer is used to simulate the low-protein conditions of the glomerular filtrate, which bathes the SGLT targets on the lumenal surface of the proximal tubule in the kidney.

Animal Study: [1]

Animal Models Normal Sprague Dawley rats or streptozotocin induced male Sprague Dawley rats
Dosages 0.01-10 mg/kg (1 mL/kg) followed by a 50% glucose solution (2 g/kg)
Administration Dosed orally
Solubility 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01606007 Recruiting Type 2 Diabetes Bristol-Myers Squibb|AstraZeneca 2012-07 Phase 3
NCT01662999 Completed Type 2 Diabetes Mellitus Bristol-Myers Squibb|AstraZeneca 2012-08 Phase 1
NCT01535677 Recruiting Type 2 Diabetes Mellitus AstraZeneca|Bristol-Myers Squibb 2013-04 Phase 1
NCT01730534 Recruiting Diabetes Mellitus, Non-Insulin-Dependent|High Risk for Cardiovascular Event AstraZeneca|Bristol-Myers Squibb|The TIMI Study Group|Hadassah Medical Organization 2013-04 Phase 3
NCT01877889 Not yet recruiting Healthy Janssen-Cilag International NV 2013-06 Phase 1

Chemical Information

Download Dapagliflozin SDF
Molecular Weight (MW) 408.87
Formula

C21H25ClO6

CAS No. 461432-26-8
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms BMS-512148
Solubility (25°C) * In vitro DMSO 82 mg/mL (200 mM)
Water <1 mg/mL (<1 mM)
Ethanol 17 mg/mL (41 mM)
In vivo 30% PEG400/0.5% Tween80/5% propylene glycol, 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.40887 4.0887 8.1774 12.2661

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related SGLT Inhibitors

  • Empagliflozin (BI 10773)

    Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.

  • Plerixafor (AMD3100)

    Plerixafor is a chemokine receptor antagonist for CXCR4 and CXCL12-mediated chemotaxis with IC50 of 44 nM and 5.7 nM, respectively.

  • GANT61

    GANT61 is an inhibitor for GLI1 as well as GLI2-induced transcription, inhibits hedgehog with IC50 of 5 μM, displays selectivity over other pathways, such as TNF and glucocorticoid receptor gene transactivation.

  • Dapagliflozin

    Dapagliflozin is a potent and selective hSGLT2 inhibitor with EC50 of 1.1 nM, exhibiting 1200-fold selectivity over hSGLT1. Phase 3.

    Features:More potent stimulator of glucosuria than other SGLT2 inhibitors.

  • Canagliflozin

    Canagliflozin is a highly potent and selective SGLT2 inhibitor for hSGLT2 with IC50 of 2.2 nM, exhibits 413-fold selectivity over hSGLT1.

  • Vismodegib (GDC-0449)

    Vismodegib (GDC-0449) is a potent, novel and specific hedgehog inhibitor with IC50 of 3 nM and also inhibits P-gp with IC50 of 3.0 μM.

  • Fingolimod (FTY720) HCl

    Fingolimod (FTY720) is a S1P antagonist with IC50 of 0.033 nM.

  • Cyclopamine

    Cyclopamine is a specific Hedgehog (Hh) signaling pathway antagonist of Smoothened (Smo) with IC50 of 46 nM.

  • LDE225 (NVP-LDE225,Erismodegib)

    LDE225 (NVP-LDE225) is a Smoothened (Smo) antagonist, inhibiting Hedgehog (Hh) signaling with IC50 of 1.3 nM (mouse) and 2.5 nM (human), respectively. Phase 3.

  • Ki16425

    Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.

Recently Viewed Items

Tags: buy Dapagliflozin | Dapagliflozin supplier | purchase Dapagliflozin | Dapagliflozin cost | Dapagliflozin manufacturer | order Dapagliflozin | Dapagliflozin distributor
Contact Us